Numbers 2 Flashcards
1
Q
% death if MCDA twins have a discordant NT >20%
A
30%
2
Q
UK CS rate
A
25%
15% EMCS
10% ELCS
3
Q
VBAC - risk of rupture 1 previous CS
A
1:200
4
Q
VBAC risk of rupture if 2 previous CS
A
1.7%
5
Q
VBAC risk of rupture if previous uterine rupture
A
5%
6
Q
VBAC risk of rupture if previous classical CS scar
A
12%
7
Q
VBAC risk of rupture if preterm
A
<0.5%
8
Q
VBAC risk of rupture with oxytocin
A
0.8%
9
Q
VBAC risk of rupture with prostaglandins
A
2.4%
10
Q
VBAC + induction increases risk of CS by
A
1.5x
11
Q
VBAC success rate
A
72-75%
12
Q
VBAC + 1 previous VD success rate
A
85-90%
13
Q
VBAC + 2 prev CS success rate
A
71%
14
Q
VBAC success rate if previous breech
A
84%
15
Q
VBAC success rate if previous fetal distress
A
74%
16
Q
VBAC success rate if previous labour dystocia
A
64%
17
Q
VBAC success rate if previous CS for dystocia, no previous VD, BMI >30 and IOL
A
40%
18
Q
VBAC success rate if >4kg EFW
A
<50%
19
Q
VBAC success rate if IUD
A
87%
20
Q
VBAC rupture rate if IUD
A
2.4%
21
Q
VBAC and instrumental delivery
A
39%
22
Q
VBAC and OASI
A
5%
23
Q
VBAC and perinatal death
A
4:10,000
24
Q
VBAC and HIE
A
8:10,000
25
VBAC and unexplained SB
10:10,000
26
Planned vaginal breech birth perinatal mortality
2:1000
27
Planned vaginal cephalic birth perinatal mortality
1:1000
28
CS >39/40 perinatal mortality
0.5:1000
29
Transient neonatal respiratory morbidity in ELCS
4-5%
30
Transient neonatal respiratory morbidity in ELCS <39/40
6%
31
Transient neonatal respiratory morbidity in ELCS at 37/40
11%
32
Risk of maternal death in ELCS
13:100,000
33
Risk of maternal death in VBAC
4:100,000
34
% CS at full dilatation
4-5%
35
% of placenta praevia at term if placenta covers os at 20/40
11%
36
% of placenta praevia if placenta covers os at 20/40, anterior placenta and previous CS
55%
37
% of hysterectomy if placenta praevia and 1 previous CS
33%
38
% of future placenta praevia in women with current placenta praevia and 1 previous CS
23%
39
% of fetal varicella syndrome if VZV infection <28/40
1%
40
Risk of ectopic with salpingostomy
20%
41
Risk of malignancy of endometrial polyp
3%
42
% of endometrial polyps in postmenopausal women
11.8%
43
% of endometrial polyps in pre-menopausal women
5.8%
44
% of PMB caused by endometrial polyps
2-12%
45
% PMB caused by endometrial hyperplasia
15%
46
Malignant potential of endometrial hyperplasia without atypia
2-5%
47
Malignant potential of endometrial hyperplasia with atpyia
23-29%
| Greentop 27.5-43% in 20yrs
48
% risk of endometrial cancer if PMB >50yo
10%
49
% risk of endometrial cancer if <50yo
1%
50
% risk of endometrial cancer in PMB >80yo
25%
51
% risk of endometrial cancer in PMB and diabetes
21%
52
% risk of endometrial cancer in PMB if diabetes and obese
29%
53
Increased risk of endometrial cancer on Tamoxifen
3-6x
| 4x when using >5years
54
% LBR in cystic fibrosis
80%
55
% PTB in cystic fibrosis
25%
56
% Spiramycin reduces risk of Toxoplasmosis fetal infection
60-70%
57
Risk of toxo transmission <4/40
<1%
58
Risk of toxo transmission 13/40
10%
59
Risk of toxo transmission 36/40
>60%
60
NICE - risk of mesh erosion in subtotal hysterectomy with sacrocolpopexy
4%
61
NICE - risk of mesh erosion in total hysterectomy with sacrocolpopexy
11%
62
NICE - risk of mesh erosion in sacrohysteropexy?
8%
63
Risk of cancer if endometrial hyperplasia doesn't regress in 12/12
23%
64
% babies colonised with chlamydia in positive mothers
50-60%
65
% chlamydia colonised babes that develop pneumonitis
15%
66
Risk of opthalmia neonatorum in gonorrhoea
28-50%
67
Transmission risk of primary HSV
40-50%
68
Transmission risk of recurrent HSV
<3%
69
Transmission risk in early syphilis
up to 100%
70
Transmission risk in late syphilis
10%
71
Transmission of primary CMV
40%
72
Transmission of recurrent CMV
1-2%
73
If falls pregnant on IUS/IUD - risk of ectopic pregnancy
1:20
74
Expulsion rate of IUS/IUD
1:20
75
Risk of uterine perforation with IUS/IUD
1:1000
76
Risk of infection with IUS/IUD
1:100
77
Use of COCP in BRCA1/2 can reduce ovarian cancer risk by
60%
78
Mesh erosion in abdominal sacrocolpopexy
2-11%
79
Re-operation rate in abdominal sacrocolpopexy
16.7%
80
Risk of anterior prolapse in SSF
8-30%
81
OASI overall %
2.9%
82
OASI in primips
6.1%
83
OASI in multips
1.7%
84
% congenital heart disease if maternal diabetes
2%
85
% congenital heart disease if 1 previous child affected
2%
86
% congenital heart disease if 2 previous children affected
10%
87
% congenital heart disease if mother has congenital heart disease
5%
88
% congenital heart disease if father has congenital heart disease
2%
89
% fetal loss with cystic hygroma
80-90%
90
% SGR occurs in monochorionic twins in absence of TTTS
15%
91
% SGR occurs sin monochorionic twins in TTTS
50%
92
% unexplained infertility
30-40%
93
% male factor as cause of infertility
30%
94
% pregnancy rates with treated lower third transverse vaginal septum
100%
95
% pregnancy rates with treated middle third transverse vaginal septum
40%
96
% pregnancy rates with treated upper third transverse vaginal septum
20%
97
Parvovirus transmission <15/40
15%
98
Parvovirus transmission 15-20/40
25%
99
Parvovirus transmission towards term
70%
100
Risk PTB <28/40 if CL at 20-24/40 <25mm
25%
101
Risk PTB <32/40 if CL at 20-24/40 <20mm
42.4%
102
Risk PTB <36/40 if CL at 20-24/40 <20mm
62%
103
% babes affected by transient neonatal myaesthenia gravis
20%
104
% unexplained infertility with mild endometriosis
30%
105
Ectopic rate in ART
2-8%
106
LBR for frozen embryos
21%
